INOTUZUMAB OZOGAMICIN

Search structure
Trade Names:
Synonyms:
Status: Approved (2017)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC26
UNII: P93RUU11P7

Pharmacology

Action Mechanism of Action Reference
BINDING AGENT CD22 binding agent
Primary Target
CD22

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 D054198 ClinicalTrials
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4 D015452 FDA
Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 D054198 ClinicalTrials
Lymphoma, Non-Hodgkin 3 D008228 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Leukemia, Biphenotypic, Acute 1 D015456 ClinicalTrials
Blast Crisis 1 D001752 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Burkitt Lymphoma 1 D002051 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Investigations
18.95
General disorders and administration site conditions
11.47
Blood and lymphatic system disorders
10.1
Infections and infestations
6.74
Metabolism and nutrition disorders
6.48
Gastrointestinal disorders
6.4
Hepatobiliary disorders
6.22
Vascular disorders
5.77
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.37
Injury, poisoning and procedural complications
4.33
Respiratory, thoracic and mediastinal disorders
3.74
Nervous system disorders
3.29
Cardiac disorders
2.78
Skin and subcutaneous tissue disorders
2.29

Cross References

Resources Reference
CAS NUMBER 635715-01-4
ChEMBL CHEMBL2108611
FDA SRS P93RUU11P7
Guide to Pharmacology 8266
CONTENTS